Published in

Springer, Annals of Surgical Oncology, 9(30), p. 5597-5609, 2023

DOI: 10.1245/s10434-023-13757-0

BMJ Publishing Group, International Journal of Gynecological Cancer, 1(20), p. 61-69, 2010

DOI: 10.1111/igc.0b013e3181c50cde

MDPI, Diagnostics, 1(10), p. 43, 2020

DOI: 10.3390/diagnostics10010043

Links

Tools

Export citation

Search in Google Scholar

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Journal article published in 2010 by van Driel Wj, Willemien J. van Driel ORCID, W. J. Van Driel, Koole Sn, J. Van Der Velden, James E. Spellman, Paul H. Sugarbaker, Karolina Sikorska, Simone N. Koole, H. Van Tinteren, Julia H. Gelissen, Naomi N. Adjei, Cyril William Helm, Blair McNamara, Jules H. Schagen van Leeuwen and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual tumor. HIPEC increases concentrations of chemotherapy directly within the peritoneal cavity compared with the intravenous route and reduces the systemic side effects associated with prolonged adjuvant intraperitoneal exposure. Furthermore, hyperthermia increases tissue penetration and is synergistic with the therapeutic chemotherapy agents used. In ovarian cancer, evidence is building for its use in both primary and recurrent scenarios. In this review, we examine the history of HIPEC, the techniques used, and the available data guiding its use in primary and recurrent ovarian cancer.